Liwanli Innovation Co (TPE:3054) ROCE %: 43.17% (As of Dec. 2025)


TPE:3054 Liwanli Innovation Co Ltd TPE:3054
61 GF Score
Price NT$61.60
GF Value NT$39.71
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Liwanli Innovation Co ROCE %?

Liwanli Innovation Co TPE:3054 -6.10% 61 ROCE % is 43.17% as of Dec. 2025. GuruFocus rates TPE:3054 with a GF Score™ of 61/100 and a GF Value™ of NT$39.71 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Liwanli Innovation Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 43.17%.

Liwanli Innovation Co  (TPE:3054) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Liwanli Innovation Co ROCE % Related Terms

Liwanli Innovation Co ROCE % Historical Data

* Premium members only.

The historical data trend for Liwanli Innovation Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liwanli Innovation Co ROCE % Chart

Liwanli Innovation Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.26 -14.34 0.68 -3.93 17.46

Liwanli Innovation Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.01 -0.40 0.51 26.11 43.17
TPE:3054
61GF Score
Liwanli Innovation Co Ltd TPE:3054
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liwanli Innovation Co ROCE % Calculation

Liwanli Innovation Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=158.937/( ( (792.189 - 33.935) + (1141.666 - 79.441) )/ 2 )
=158.937/( (758.254+1062.225)/ 2 )
=158.937/910.2395
=17.46 %

Liwanli Innovation Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=421.2/( ( (921.629 - 32.691) + (1141.666 - 79.441) )/ 2 )
=421.2/( ( 888.938 + 1062.225 )/ 2 )
=421.2/975.5815
=43.17 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 43.17% mean?
Liwanli Innovation Co (TPE:3054) has a ROCE % of 43.17% as of Dec. 2025.
Is Liwanli Innovation Co's ROCE % too high?
Liwanli Innovation Co's current ROCE % is 43.17%. The Drug Manufacturers industry median ROCE % is 7.00. Liwanli Innovation Co's value of 43.17% is 517.2% above this industry median. Overall, Liwanli Innovation Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's ROCE % compare to ZTS?
Liwanli Innovation Co's ROCE % of 43.17% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Liwanli Innovation Co's value of 43.17% is 517.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current ROCE % of 43.17% is 517.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current ROCE % is 43.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.71, compared to a current price of NT$61.60 — trading 55.1% above its estimated fair value. The current ROCE % is 43.17% and 517.2% above the Drug Manufacturers industry median of 7.00. Liwanli Innovation Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current ROCE % is 43.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?

Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be overvalued. The current stock price of NT$61.60 is trading 55.1% above its estimated GF Value™ of NT$39.71. GuruFocus considers Liwanli Innovation Co to be Significantly Overvalued.

Key valuation signals for TPE:3054:

  • ROCE %: 43.17%
  • GF Value™: NT$39.71 vs. price of NT$61.60 (55.1% above fair value)
  • GF Score™: 61/100 with 2 warning signs
  • Industry Position: 517.2% above the Drug Manufacturers median

No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Liwanli Innovation Co Business Description

Address No. 537, Tanmei Street, 9th Floor, Neihu District, Taipei City, TWN, 235
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
61GF Score

Get the complete analysis for TPE:3054

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$61.60
Price
NT$39.71
GF Value